Eli Lilly and Company LLY SPX
Company Overview
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; and strategic collaboration with Ascidian Therapeutics for discovery and development of therapies for undisclosed monogenic kidney diseases. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Why Investors Should Care
Generates a return on equity of 107.5%, reflecting efficient use of shareholder capital.
Net profit has compounded at 11.4% per year over the last five years.
Maintains a net profit margin of 35.0%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $65.18B (+44.7% YoY); net profit $20.64B.
- Trailing 12 Months Year-on-year growth — revenue +55.5%, earnings +169.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.2%, profit CAGR 11.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.20% |
| 1 Year: | 55.50% |
Compounded Profit Growth
| 5 Years: | 11.41% |
| 1 Year: | 169.90% |
Stock Price Performance
| 1 Year: | +45.21% |
| 6 Months: | +8.73% |
| 3 Months: | +24.20% |
| 1 Month: | -0.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.61 · Neutral
P/E of 41.02 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 107.5%.
- Excellent profit margin of 35.0%.
- Profit CAGR of 11.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 2 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 3 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 5 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 6 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 7 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 8 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
| 9 | GILD Gilead Sciences, Inc. NDXSPX | 130.04 | 17.69 | $161.45B | 2.61% | 21.23% | 43.36% | 11.38% | 9.79% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.12B | 4.64B | 4.98B | 4.96B | 5.38B | 4.87B | 5.40B | 5.19B | 5.76B | 5.23B | 5.82B | 5.66B | 6.16B | 4.96B | 5.58B | 5.31B | 5.64B | 5.09B | 5.64B | 5.48B | 6.11B | 5.86B | 5.50B | 5.74B | 6.81B | 6.74B | 6.77B | 7.81B | 6.49B | 6.94B | 6.96B | 8.31B | 9.50B | 8.77B | 11.30B | 11.44B | 12.73B | 15.56B | 17.60B | 19.80B |
| Net Income | 428.50M | 529.50M | 600.80M | 799.70M | 478.40M | 440.10M | 747.70M | 778.00M | 771.80M | -110.80M | 1.01B | 555.60M | - | 1.22B | -259.90M | 1.15B | - | 4.24B | 1.33B | 1.25B | - | 1.46B | 1.41B | 1.21B | 1.36B | 1.39B | 1.11B | 1.90B | 952.50M | 1.45B | 1.34B | 1.76B | -57.40M | 2.24B | 2.97B | 970.30M | 2.76B | 5.66B | 5.58B | 7.40B |
| Diluted EPS | 0.40 | 0.50 | 0.56 | 0.75 | 0.45 | 0.41 | 0.71 | 0.73 | 0.73 | -0.10 | 0.95 | 0.53 | -1.58 | 1.16 | -0.25 | 1.12 | 1.10 | 4.31 | 1.44 | 1.37 | 1.64 | 1.60 | 1.55 | 1.33 | 1.49 | 1.53 | 1.22 | 2.10 | 1.05 | 1.61 | 1.49 | 1.95 | -0.06 | 2.48 | 3.28 | 1.07 | 3.06 | 6.29 | 6.21 | 8.26 |
| R&D Expense | - | 1.04B | 1.17B | 1.14B | - | 1.22B | 1.34B | 1.24B | - | 1.26B | 1.27B | 1.34B | - | 1.11B | 1.27B | 1.28B | - | 1.23B | 1.40B | 1.38B | - | 1.39B | 1.39B | 1.47B | 1.67B | 1.66B | 1.71B | 1.61B | 1.78B | 1.80B | 1.99B | 2.36B | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.63B | 20.37B | 21.84B | 23.08B | 24.29B | 22.60B | 23.11B | 19.62B | 19.96B | 21.22B | 19.97B | 21.49B | 22.32B | 24.54B | 28.32B | 28.54B | 34.12B | 45.04B | 65.18B |
| Net Income | 2.95B | -2.07B | 4.33B | 5.07B | 4.35B | 4.09B | 4.68B | 2.39B | 2.41B | 2.74B | -204.10M | 3.23B | 8.32B | 6.19B | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B |
| Diluted EPS | - | -1.89 | 3.94 | 4.58 | 3.90 | 3.66 | 4.32 | 2.23 | 2.26 | 2.58 | -0.19 | 3.13 | 8.89 | 6.79 | 6.12 | 6.90 | 5.80 | 11.71 | 22.95 |
| R&D Expense | 3.49B | 3.84B | 4.33B | 4.88B | 5.02B | 5.28B | 5.53B | 4.73B | 4.80B | 5.31B | 5.10B | 5.05B | 5.59B | 5.98B | 6.93B | 7.19B | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 29.21B | 27.46B | 31.00B | 33.66B | 34.40B | 35.25B | 36.31B | 35.57B | 38.81B | 44.98B | 43.91B | 39.29B | 46.63B | 48.81B | 49.49B | 64.01B | 78.72B | 112.48B |
| Total Equity | - | - | 6.74B | 9.53B | 12.42B | 13.54B | 14.77B | 17.63B | 15.37B | 14.57B | 14.01B | 11.59B | 9.83B | 2.61B | 5.64B | 8.98B | 10.65B | 10.77B | 14.27B | 26.54B |
| Cash & Equivalents | 3.11B | 3.22B | 5.50B | 4.46B | 5.99B | 5.92B | 4.02B | 3.83B | 3.87B | 3.67B | 4.58B | 6.54B | 7.32B | 2.34B | 3.66B | 3.82B | 2.07B | 2.82B | 3.27B | 7.27B |
| Long Term Debt | - | - | 4.62B | 6.63B | 6.77B | 5.46B | 5.52B | 4.20B | 5.33B | 7.97B | 8.37B | 9.94B | 9.20B | 13.82B | 16.59B | 15.35B | 14.74B | 18.32B | 28.53B | 40.87B |
| Current Liabilities | - | - | 13.11B | 6.57B | 6.93B | 8.93B | 8.39B | 8.92B | 9.74B | 8.23B | 10.99B | 14.54B | 11.89B | 11.78B | 12.48B | 15.05B | 17.14B | 27.29B | 28.38B | 35.23B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.15B | 7.30B | 4.34B | 6.86B | 7.23B | 5.30B | 5.74B | 4.46B | 2.96B | 4.85B | 5.62B | 5.52B | 4.84B | 6.50B | 7.37B | 7.59B | 4.24B | 8.82B | 16.81B |
| Investing Cash Flow | -4.33B | -7.27B | 142.80M | -3.16B | -4.82B | -2.83B | -2.07B | -3.91B | 26.80M | -3.14B | -3.78B | 1.91B | -8.08B | -2.26B | -2.87B | -3.76B | -7.15B | -9.30B | -10.97B |
| Financing Cash Flow | -844.90M | 2.35B | -5.53B | -2.02B | -2.37B | -4.42B | -3.83B | -166.40M | -3.11B | -559.80M | 142.60M | -5.90B | -2.32B | -3.14B | -4.13B | -5.41B | 3.50B | 1.23B | -2.21B |
| Share Buybacks | - | - | - | 0 | 0 | 721.10M | 1.70B | 800.00M | 749.50M | 600.10M | 299.80M | 4.15B | 4.40B | 500.00M | 1.25B | 1.50B | 750.00M | 2.50B | 4.11B |
| Dividends Paid | 1.85B | 2.06B | 2.15B | 2.17B | 2.18B | 2.19B | 2.12B | 2.10B | 2.13B | 2.16B | 2.19B | 2.31B | 2.41B | 2.69B | 3.09B | 3.54B | 4.07B | 4.68B | 5.38B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | 15.8% | -10.2% | 19.8% | 22.0% | 17.9% | 18.1% | 20.3% | 12.2% | 12.1% | 12.9% | -1.0% | 15.0% | 37.3% | 25.2% | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| ROE % | - | -30.8% | 45.4% | 40.8% | 32.1% | 27.7% | 26.6% | 15.5% | 16.5% | 19.5% | -1.8% | 32.9% | 319.1% | 109.8% | 62.2% | 58.6% | 48.6% | 74.2% | 77.8% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Lilly Endowment, Inc | 9.76% | 91.90M | $109.94B |
| 2 | Blackrock Inc. | 7.05% | 66.38M | $79.42B |
| 3 | Vanguard Capital Management LLC | 5.67% | 53.36M | $63.84B |
| 4 | PNC Financial Services Group, Inc. | 5.45% | 51.33M | $61.41B |
| 5 | State Street Corporation | 3.78% | 35.61M | $42.60B |
| 6 | FMR, LLC | 2.80% | 26.34M | $31.51B |
| 7 | Capital Research Global Investors | 2.62% | 24.63M | $29.47B |
| 8 | Vanguard Portfolio Management LLC | 2.23% | 20.98M | $25.10B |
| 9 | Geode Capital Management, LLC | 2.14% | 20.19M | $24.16B |
| 10 | Capital World Investors | 1.66% | 15.62M | $18.69B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LLY
Is Lilly Stock On Track To Hit $2,090? - Forbes
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNUWNTSGpDSmR1MjdkSzd0VWpyaGdmWnBVYkt5T1R6dzYzdW1BdGtITHRkQUZseTNJRUFDdUYzcWdVVFpUcHVHal9lQmtlS3FhTG1CRURjVlhaOHdXM0RoRUhPRE5oLTFRVVRvVEg3ZjdGUTdaVUhaZ0lPSTVKR1c5M2ViTlNIbnNOQ1RESV…
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTFB4V0NTN3l5MlJIbXdZdjZkSkxwQnlBQzI4M3FyOXcxbzlfOXZaRFhlelRaV0FoWC00akxiZC1VRVEwMTBia0FjYVFXeUF6TldjcGVsTGtPUm1XRlp5Z0tldXM5Uk9yTVpmRjlvRllMcHBuNjBfY2ZQSW9IVXQwUQ?oc=5" target="_blan…
Eli Lilly & Co. (NYSE:LLY) Passes Navellier’s High-Growth Screen on Strong Earnings and Sales Momentum - ChartMill
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNSlA1elMtcXdvUHlGZzBMWC1tRHdTamJRdEhJazJYdzVBckMtTl9CLTEyZk5xNjM5TkFySXVvYlBRZ2h3clhwRzYzbncyMG9pOUZnbUhsMXlSN0txcFhRUDh6czRWbzVqeWlvN3lGSE5DaThwbVZhR3pjVC1KWkJFY21Wa1pTS0c5dUVfSU…
How Does LLY Stock Reach $2,100? - Trefis
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPUEZoRGZyM2FtcGxKMTM0TmRHTnFXT1NiWFN0NmhCTmZMbi0wWXJMelB5bkVXZG9ObEtaTlV0UGRRV0dzaXc2VTJQS2ZNc1N3TkhmM0E2SEp6VHhRTzhWMUlhd3Z4Q2dZaG9lUXN0VUF2LS1URHNzRlVwTW1DN1Z1dzhRMWJURXhMNEFyNU…
Eli Lilly Stock (LLY) Opinions on Analyst Upgrades and Biotech Momentum - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOYTZlNkhMMm11N0c2aTlqVWpkbl9IRkc2WTRMQlkxRjVVdmRXVnpWLU13ZE1PMm9kaHFQTFVBZHBhTDg4clU1Wm1JVDY3NHdIeW1IVTQ1ZXBIc3NJMks2Z2YwbnBsdm4wN214aFRjVk8yWVhPOGZ5d0dLSEdzQmNlVXFyQ3NPckk5TjZNSz…
Eli Lilly and Co Stock (LLY) Moved Down by 3.10% on Jul 14: Facts Behind the Movement - TradingKey
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxORzBmMzJObXd3bkVKWlJISHVPdmVQMDZfa2hsa0pyNklVYzh1NG9FWThEYWZhU2RaSXl6TmtndXNHa3pHMEo1cUQ1NUNnUG1fVEdtWHAwSXEzS0JUeS0wc0x5eWdBUHVyZkQyY2FDZlBsek91M0tRMmVHU1lpVnhTUFhiNGttdy1nVkE?oc…
LLY — Frequently Asked Questions
What is the current share price of Eli Lilly and Company (LLY)?
As of 2026-07-14 21:23 PDT, Eli Lilly and Company (LLY) trades at $1,152.54 on NYSE. Its 52-week range is $621.26 to $1,235.56.
What is the market capitalisation of LLY?
Eli Lilly and Company (LLY) has a market capitalisation of $1.03T on NYSE.
What is the P/E ratio of LLY?
LLY trades at a trailing price-to-earnings (P/E) ratio of 41.02. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 32.45.
Does LLY pay a dividend?
Eli Lilly and Company (LLY) currently offers a dividend yield of 0.61%.
What is the return on equity (ROE) of LLY?
LLY has a return on equity (ROE) of 107.46%.
Is LLY a good stock to buy?
This page provides a data-driven analysis of Eli Lilly and Company (LLY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.